Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
October 24, 2024 09:15 ET
|
Cyclacel
CYCLACEL PHARMACEUTICALS ANNOUNCES THAT NASDAQ GRANTED AN EXTENSION TO REGAIN COMPLIANCE WITH THE EQUITY STANDARD RULE
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
October 23, 2024 09:15 ET
|
Cyclacel
NEW CLINICAL DATA FROM ONGOING, PHASE 2 STUDY OF ORAL FADRACICLIB AT THE 2024 ENA SYMPOSIUM.
Patients preselected for CDKN2A and/or CDKN2B abnormalities
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
October 09, 2024 09:15 ET
|
Cyclacel
Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
September 25, 2024 09:15 ET
|
Cyclacel
Cyclacel announces completion of enrollment in the biomarker-enriched
cohort of its Phase 2 study
- Patients are preselected for C
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024 09:15 ET
|
Cyclacel
Cyclacel to participate at the H.C. Wainwright 26th Annual Global Investment Conference
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
September 03, 2024 09:15 ET
|
Cyclacel
Cyclacel timely appeals against Nasdaq delisting letter. Delisting stayed until Nasdaq hearing panel determination
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
August 14, 2024 16:05 ET
|
Cyclacel
Cyclacel provides Q2 2024 financial results and business update on fadraciclib precision medicine strategy
Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
August 07, 2024 09:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
June 26, 2024 09:15 ET
|
Cyclacel
NOTICE OF INTENTION TO GRANT OF NEW EUROPEAN PATENT
COVERING PLOGOSERTIB PHARMACEUTICAL COMPOSITIONS
- Lengthens Patent Exclusivity to August 2040
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
June 04, 2024 08:00 ET
|
Cyclacel
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) --...